Limited Near-Term Visibility and Execution Risk Drive Sell Rating on Evotec Despite In-Line Results

Bank of America Securities analyst Michael Ryskin reiterated a Sell rating on Evotec AG yesterday and set a price target of $3.00.

Michael Ryskin has given his Sell rating due to a combination of factors tied to Evotec’s limited near‑term visibility and execution risk. Although FY25 results were roughly in line and FY26 guidance was reaffirmed, the outlook assumes a pronounced rebound in the second half of the year, which depends on a recovery in early-stage demand and improved performance across major initiatives.

He highlights that early discovery activity remains subdued, biotech funding is inconsistent, and key partnerships like BMS are contributing less as programs move into lower-revenue phases, all of which pressure margins and growth. In addition, the Horizon restructuring is expected to yield most of its benefits only from 2027 onward, while associated costs and complexity weigh on profitability, leading him to see limited upside at the current valuation and maintain an Underperform stance with a modest price objective.